The University of Oxford said on Tuesday it had paused a small UK trial testing the COVID-19 vaccine it developed with AstraZeneca in children and teenagers, as it waits for more data on rare blood clotting issues in adults who received the shot.
The trial disruption is the latest blow to the vaccine, once hailed as a milestone in the fight against the pandemic, after several countries restricted its use in light of reports of medical issues after inoculations.
There were no safety concerns in the pediatric trial, Oxford University said, adding that it would await guidance from the UK drugs watchdog before giving any further vaccinations.
The university said in February it planned to enroll 300 volunteers aged 6-17 years, based in the United Kingdom, as part of this study.
The European Medicines Agency (EMA) is currently reviewing reports of an extremely rare brain blood clot known as cerebral venous sinus thrombosis (CVST) after the AstraZeneca shots, and is expected to announce its findings on Wednesday or Thursday.
A senior EMA official has said there is a clear association between the vaccine and CVST, though the direct cause of the clots is still unknown.
The World Health Organization, which is closely studying the latest data on AstraZeneca’s vaccine alongside other regulators, said on Tuesday it expects to there will be no reason to change its assessment that the shot’s benefits outweigh any risks.
Spats with governments across Europe about production, supplies, possible side effects and the vaccine’s merits have dogged the Anglo-Swedish drugmaker for months.
Anthony Fauci, the top US infectious disease doctor, told Reuters last week the United States may not need AstraZeneca’s vaccine, even if it wins regulatory approval.
Almost one in seven suffers long COVID-19, UK study findsNearly one in seven Britons who tested positive for Covid-19 continued to have symptoms for at least 12 weeks, according to a UK study released ... Coronavirus
Children 10 and younger have stronger antibody response to COVID-19: StudyChildren who are 10 and younger produce more antibodies in response to coronavirus infection than adolescents and adults, a study showed Monday.The ... Coronavirus
UK COVID-19 variant has significantly higher death rate: StudyA highly infectious variant of COVID-19 that has spread around the world since it was first discovered in Britain late last year is between 30 percent ... Coronavirus
German experts say under 60s should not get 2nd AstraZeneca vaccineGermany's vaccine commission, known as STIKO, recommended on Thursday that people under 60-years old who have had a first shot of AstraZeneca's ... Coronavirus
No clotting risk factor yet linked to AstraZeneca vaccine, says EU drug watchdogEurope’s medicines regulator said on Wednesday it had not yet identified any risk factors such as age, sex or a previous history of blood clotting ... Coronavirus